Long-term follow-up results of growth hormone therapy for patients with adult growth hormone deficiency

Ikeda, Hidetoshi; Kudo, Masataka

doi:10.1007/bf03401402

Cited by 6 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is important to note that adult patients with GHD often have a low perceived QOL. rh-GH replacement therapy elicited significant changes in body composition, and the physical and psychosocial QOL [39]. These measures may further validate the efficacy of rh-GH replacement therapy.…”

Section: Discussionmentioning

confidence: 81%

Effect of growth hormone replacement therapy on plasma diacron-reactive oxygen metabolites and endothelial function in Japanese patients: The GREAT clinical study

et al. 2018

View full text Add to dashboard Cite

Abstract. Patients with growth hormone deficiency (GHD) have an increased risk of atherosclerosis and vascular mortality. Evidence suggests that endothelial dysfunction is involved in all stages of atherogenesis. This study examined the effect of growth hormone (GH) replacement therapy on diacron-reactive oxygen metabolites (d-ROMs) and endothelial function in Japanese patients with GHD, using peripheral arterial tonometry. This was an open-label, prospective, case-control study. Nine patients with GHD who had not previously received any GH replacement therapy were enrolled. The following parameters were evaluated at baseline (before treatment), and after 24 weeks of GH replacement therapy: endothelial function using the reactive hyperemia index (RHI; EndoPAT ® system), d-ROMs, blood pressure, and fasting lipid levels. Plasma GH and insulin-like growth factor-1 (IGF-1) levels were measured at baseline and after 24 weeks of GH replacement therapy. We also enrolled eight controls with pituitary disease but no GH deficiency. Over 24 weeks of GH replacement therapy, the serum IGF-1 levels normalized with significant improvement in the RHI (from 1.65 ± 0.33 to 1.92 ± 0.26, p < 0.05) and decreased d-ROM levels (from 356.8 ± 64.1 to 303.1 ± 43.3 U.CARR, p < 0.05). There were no significant improvements in the RHI or d-ROM levels in controls. GH replacement therapy in Japanese patients with GHD may be mediated by the reduced oxidative stress and the d-ROMs associated with the treatment.

show abstract

Section: Discussionmentioning

confidence: 81%

Effect of growth hormone replacement therapy on plasma diacron-reactive oxygen metabolites and endothelial function in Japanese patients: The GREAT clinical study

et al. 2018

View full text Add to dashboard Cite

show abstract

“…It is also involved in the regulation of blood glucose, de-creasing the ability of insulin to increase the uptake of glucose in peripheral tissues [9]. This hormone plays an important role in the regulation of anabolism and in the preservation of lean mass, and some of these anabolic effects are mediated by stimulation of lipolysis.…”

Section: Gh/igf-1 Axismentioning

confidence: 99%

Growth Hormone Replacement Therapy in Patients without Adult Growth Hormone Deficiency: What Answers Do We Have So Far?

Rucker¹,

Sá²,

Arbex³

2017

Health

View full text Add to dashboard Cite

Growth hormone (GH) and insulin-like growth factor 1 (IGF-1) have been suggested as "anti-aging" therapies, or for improving quality of life with aging. In this study, we focus on the actions of GH in the main organs and organ systems of the human body, like skeletal muscle, bones and brain, particularly in regard to data and research on the use of GH replacement therapy in adults without growth hormone deficiency, especially elderly patients. Several different studies have been carried out to show what the effects and side effects of GH replacement in healthy people and what would be the impact in quality of life and life span. In this review, we demonstrate what answers we have so far about the effects of GH replacement in many organs and systems in healthy people.

show abstract

“…Negative impacts of AGHD on patient physiology, psychological well-being, cognitive functioning, and QoL are well documented; however, studies suggest that growth hormone (GH) treatments can be effective in mitigating poorer health outcomes [15, 16]. In fact, a recent study investigated the long-term effects of growth hormone treatment on adults with GHD and found the effect of GH therapy on QoL showed sequential improvements and stabilization until 6-year follow-up [17].…”

Section: Introductionmentioning

confidence: 99%

Assessing the Impact of Growth Hormone Deficiency (GHD) in Adults: Interpreting Change of the Treatment-Related Impact Measure—Adult Growth Hormone Deficiency (TRIM-AGHD)

Brod

Beck

Højbjerre

et al. 2018

PharmacoEconomics Open

View full text Add to dashboard Cite

Background This study's purpose was to assess the minimal important difference (MID) for the Treatment-Related Impact Measure-Adult Growth Hormone Deficiency (TRIM-AGHD), a patient-reported outcome measure assessing growth hormone deficiency (GHD) impacts. The measure was demonstrated to have adequate psychometric measurement properties, and be reliable and valid. For scores to be interpretable, the TRIM-AGHD must be responsive to treatment benefit and the MID in scores quantified. Methods A prospective, non-interventional, observational, clinic-based survey study of naïve-to-treatment adult GHD patients (N = 98) was conducted. Key assessments were at baseline and follow-up (between 4 and approximately 8 weeks), with weekly telephone monitoring post-baseline (last n = 34 patients). Responsiveness was evaluated using the effect size of change scores from baseline to follow-up. MID estimates were derived from distribution-based (half standard deviation [0.5 SD], standard error of measurement [SEm]) and anchor-based methods (patient global rating of change [PGRC]) using change scores from baseline to initial report of minimal improvement in GHD severity.Findings from each method were converged to establish an acceptable MID. Results Patients were mean age 49.7 years, 65.6% female, and 76.0% Caucasian. The TRIM-AGHD was highly responsive to treatment with the total score effect size being 1.38. For the total score, the 0.5 SD was 8.09 and the SEm was 2.66. The difference found using the PGRC was 20.43. The converged MID value for the total score was 10 points. Conclusions The TRIM-AGHD is a highly responsive measure assessing AGHD treatment impacts. A 10-point change score is considered a clinically meaningful improvement. Key Points for Decision MakersFor survey scores to be interpretable, the minimal important difference (MID) in scores must be quantified, which is the smallest change in a score for a patient that indicates an actual change between two time points.The MID allows both researchers and clinicians to interpret if treatment plans are effective.

show abstract

Long-term follow-up results of growth hormone therapy for patients with adult growth hormone deficiency

Cited by 6 publications

References 15 publications

Effect of growth hormone replacement therapy on plasma diacron-reactive oxygen metabolites and endothelial function in Japanese patients: The GREAT clinical study

Effect of growth hormone replacement therapy on plasma diacron-reactive oxygen metabolites and endothelial function in Japanese patients: The GREAT clinical study

Growth Hormone Replacement Therapy in Patients without Adult Growth Hormone Deficiency: What Answers Do We Have So Far?

Assessing the Impact of Growth Hormone Deficiency (GHD) in Adults: Interpreting Change of the Treatment-Related Impact Measure—Adult Growth Hormone Deficiency (TRIM-AGHD)

Contact Info

Product

Resources

About